| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $67,538,602 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264987 | Radiomic and genomic predictors of breast cancer risk | 001 | 6 | NIH | 4/16/2026 | $69,765 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264987 | Radiomic and genomic predictors of breast cancer risk | 000 | 6 | NIH | 1/15/2026 | $627,887 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HD112473 | Role of PRMT7 in Genomic Imprinting | 000 | 4 | NIH | 5/7/2026 | $348,300 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA289456 | Targeting the gut microbiome to inhibit melanoma lymph node metastases | 000 | 3 | NIH | 5/19/2026 | $515,112 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279194 | Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC. | 000 | 4 | NIH | 4/27/2026 | $370,575 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK132019 | Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes | 000 | 3 | NIH | 4/17/2026 | $398,433 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK132019 | Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes | 001 | 3 | NIH | 4/29/2026 | $187,920 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HD110520 | Molecular Mechanism of long Noncoding RNAs in Phenylketonuria | 001 | 4 | NIH | 3/27/2026 | $46,592 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HD110520 | Molecular Mechanism of long Noncoding RNAs in Phenylketonuria | 000 | 4 | NIH | 1/28/2026 | $419,339 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31HD113306 | Molecular and Cellular Regulation of Uterine Morphogenesis | 001 | 3 | NIH | 4/1/2026 | $576 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31HD113306 | Molecular and Cellular Regulation of Uterine Morphogenesis | 000 | 3 | NIH | 1/22/2026 | $37,524 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA275822 | A radiation oncology clinician scientist devoted to building a clinical research program in an integrated academic satellite network in service to the National Cancer Institute | 000 | 4 | NIH | 3/3/2026 | $86,702 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA293361 | Modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer | 000 | 1 | NIH | 4/2/2026 | $660,541 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31AR087163 | Investigating the role of O-GlcNAc in silencing retrotransposons in the skin | 000 | 1 | NIH | 5/14/2026 | $38,189 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31AR087163 | Investigating the role of O-GlcNAc in silencing retrotransposons in the skin | 001 | 1 | NIH | 5/21/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299449 | Computational Approaches to Reconstruct the Evolutionary History of Cancer Metastases | 000 | 1 | NIH | 5/5/2026 | $688,073 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 4 | NIH | 2/27/2026 | $480,324 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 2 | NIH | 3/3/2026 | $676,584 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 000 | 5 | NIH | 2/26/2026 | $577,370 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25CA181004 | MD Anderson Science Park Summer Program in Cancer Research SPCR | 000 | 12 | NIH | 5/5/2026 | $242,094 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 4 | NIH | 1/23/2026 | $444,596 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 001 | 4 | NIH | 4/16/2026 | $47,386 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 4 | NIH | 1/20/2026 | $426,474 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 4 | NIH | 2/27/2026 | $395,807 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 001 | 4 | NIH | 4/16/2026 | $49,400 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 001 | 6 | NIH | 4/16/2026 | $40,867 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 6 | NIH | 1/28/2026 | $367,804 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA303068 | Study of a new driver and therapeutic vulnerability of bone metastasis | 000 | 2 | NIH | 5/12/2026 | $564,695 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295834 | Endogenous Circular RNAs limit abemaciclib anti tumor immune responses | 000 | 2 | NIH | 2/26/2026 | $567,059 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08HL169905 | Investigating High-Risk Epigenetic Modifying Alterations on JAK2VF Dependency and Fibrotic Progression in Myeloproliferative Neoplasms (MPNs) | 000 | 3 | NIH | 2/9/2026 | $167,616 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA207295 | DNA damaging therapy and immune response in small cell lung cancer subtypes | 000 | 10 | NIH | 3/4/2026 | $387,250 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 5 | NIH | 2/24/2026 | $556,146 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 000 | 3 | NIH | 3/4/2026 | $370,575 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA248289 | Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | 001 | 8 | NIH | 6/3/2026 | $584,756 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI190103 | Machine learning for identifying antigen-antibody interactions from massive sequencing data | 003 | 3 | NIH | 2/24/2026 | $635,012 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 001 | 2 | NIH | 4/16/2026 | $67,755 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 000 | 2 | NIH | 1/28/2026 | $609,807 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 000 | 5 | NIH | 3/31/2026 | $514,261 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 001 | 2 | NIH | 4/16/2026 | $11,203 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 2 | NIH | 2/6/2026 | $100,823 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA287279 | Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer | 000 | 2 | NIH | 3/27/2026 | $679,129 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 000 | 2 | NIH | 2/20/2026 | $618,871 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 001 | 2 | NIH | 4/16/2026 | $52,725 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 000 | 2 | NIH | 1/26/2026 | $474,524 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01GM152497 | Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | 000 | 3 | NIH | 4/21/2026 | $292,599 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA200462 | MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm | 001 | 9 | NIH | 6/5/2026 | $1,112,552 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K01AI166096 | Bacteriophages as Modulators of Bacterial Colonization | 001 | 5 | NIH | 12/23/2025 | $105,792 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA271187 | Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy | 000 | 5 | NIH | 5/28/2026 | $486,613 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Access to Fertility Specialty Care Among Cancer Survivors | 000 | 4 | NIH | 3/2/2026 | $497,133 |
|
